Literature DB >> 12918550

Benign essential blepharospasm among residents of Olmsted County, Minnesota, 1976 to 1995: an epidemiologic study.

Elizabeth A Bradley1, David O Hodge, George B Bartley.   

Abstract

PURPOSE: To describe the incidence, patient demographics, and response to treatment of benign essential blepharospasm (BEB) in a population-based cohort.
METHODS: In this epidemiologic study, we searched the Rochester Epidemiology Project database for patients diagnosed with blepharospasm or related disorders between 1976 and 1995. The incident rate denominator was based on a linear interpolation of decennial census data from Olmsted County. The 95% confidence interval for the incidence rate was based on the Poisson distribution.
RESULTS: Olmsted County residents (n = 295) were diagnosed with blepharospasm or related disorders between 1976 and 1995. Of these, 8 patients met the criteria for BEB. The calculated incidence rate of BEB is 1.2 persons per 100,000 population per year (95% CI, 0.37 to 2.02). At the time of BEB diagnosis, the median patient age was 61.5 years, and symptoms had been present for a median of 24 months. Four patients were men and 4 were women. Four of the 8 patients had Meige syndrome. Three of 4 patients treated with oral medications reported symptomatic improvement. Botulinum toxin injection was offered to all patients, but only 4 elected treatment. All who were treated with botulinum toxin had temporary symptomatic improvement. No patient underwent surgical treatment for BEB. Two patients had resolution of symptoms within the follow-up period.
CONCLUSIONS: BEB is a rare disorder. In this small, population-based sample, women and men were affected with equal frequency, and half of patients had lower facial dystonia (Meige syndrome). Only half of patients with BEB elected botulinum toxin injections, and none required surgery. Disease remission occurred in 2 of 8 patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918550     DOI: 10.1097/01.iop.0000065203.88182.cf

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  4 in total

Review 1.  Botulinum toxin in the management of blepharospasm: current evidence and recent developments.

Authors:  Amy Hellman; Diego Torres-Russotto
Journal:  Ther Adv Neurol Disord       Date:  2015-03       Impact factor: 6.570

2.  Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China.

Authors:  Xiao-Bo Fang; Meng-Shu Xie; Zu-Biao Song; Zhi-Gang Zhong; Ying Wang; Zi-Lin Ou; Chao Dang; Ling Li; Wei-Xi Zhang
Journal:  Neurol Sci       Date:  2019-11-19       Impact factor: 3.307

3.  Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm.

Authors:  Jeremy Clark; John Randolph; Jason A Sokol; Nicholas A Moore; Hui Bae H Lee; William R Nunery
Journal:  Digit J Ophthalmol       Date:  2017-11-05

4.  Epidemiology of benign essential blepharospasm: A nationwide population-based retrospective study in Taiwan.

Authors:  Yng Sun; Pei-Jhen Tsai; Chin-Liang Chu; Wei-Chun Huang; Youn-Shen Bee
Journal:  PLoS One       Date:  2018-12-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.